<i>Ex Vivo</i> PD-L1/PD-1 Pathway Blockade Reverses Dysfunction of Circulating CEA-Specific T Cells in Pancreatic Cancer Patients
<i>Ex Vivo</i> PD-L1/PD-1 Pathway Blockade Reverses Dysfunction of Circulating CEA-Specific T Cells in Pancreatic Cancer Patients is a paper indexed in PICO Portal from OpenAlex.
How many citations does <i>Ex Vivo</i> PD-L1/PD-1 Pathway Blockade Reverses Dysfunction of Circulating CEA-Specific T Cells in Pancreatic Cancer Patients have?
<i>Ex Vivo</i> PD-L1/PD-1 Pathway Blockade Reverses Dysfunction of Circulating CEA-Specific T Cells in Pancreatic Cancer Patients has 13 citations in the OpenAlex counts PICO Portal stores.
When was <i>Ex Vivo</i> PD-L1/PD-1 Pathway Blockade Reverses Dysfunction of Circulating CEA-Specific T Cells in Pancreatic Cancer Patients published?
<i>Ex Vivo</i> PD-L1/PD-1 Pathway Blockade Reverses Dysfunction of Circulating CEA-Specific T Cells in Pancreatic Cancer Patients has 2017 year in the PICO Portal index.
What is the open-access status of <i>Ex Vivo</i> PD-L1/PD-1 Pathway Blockade Reverses Dysfunction of Circulating CEA-Specific T Cells in Pancreatic Cancer Patients?
<i>Ex Vivo</i> PD-L1/PD-1 Pathway Blockade Reverses Dysfunction of Circulating CEA-Specific T Cells in Pancreatic Cancer Patients has bronze oa status in the PICO Portal index.
What is the DOI of <i>Ex Vivo</i> PD-L1/PD-1 Pathway Blockade Reverses Dysfunction of Circulating CEA-Specific T Cells in Pancreatic Cancer Patients?
The DOI for <i>Ex Vivo</i> PD-L1/PD-1 Pathway Blockade Reverses Dysfunction of Circulating CEA-Specific T Cells in Pancreatic Cancer Patients is on the source record.
What is the PMID of <i>Ex Vivo</i> PD-L1/PD-1 Pathway Blockade Reverses Dysfunction of Circulating CEA-Specific T Cells in Pancreatic Cancer Patients?
The PMID for <i>Ex Vivo</i> PD-L1/PD-1 Pathway Blockade Reverses Dysfunction of Circulating CEA-Specific T Cells in Pancreatic Cancer Patients is on the source record.
What is the OpenAlex record for <i>Ex Vivo</i> PD-L1/PD-1 Pathway Blockade Reverses Dysfunction of Circulating CEA-Specific T Cells in Pancreatic Cancer Patients?
The OpenAlex for <i>Ex Vivo</i> PD-L1/PD-1 Pathway Blockade Reverses Dysfunction of Circulating CEA-Specific T Cells in Pancreatic Cancer Patients is on the source record.